Price Cuts For Daewoong As Korea Attacks Rebates
This article was originally published in PharmAsia News
South Korea's Ministry of Health and Welfare will cut the prices of five products from Daewoong Pharmaceutical by 20% from May following a Seoul court's ruling last year that found the pharma firm guilty of providing illegal rebates in return for prescriptions.
You may also be interested in...
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.